Landauer — FY2011 Earnings Presentation
14 slides from Landauer's earnings presentation, Dec 7, 2011
Slide 1: Fiscal 2011 Fourth Quarter and Year End Results
LANDAUER, INC. Fiscal 2011 Fourth Quarter and Year End Results December 6 th , 2011
Slide 2: Safe Harbor Statement
This presentation may contain forward-looking statements, including statements about the outlook and prospects for Company and industry growth, as well as statements about the Company’s future financial and operating performance. Some of the information shared here constitutes forward-looking statem
Slide 3: Recent Financial Performance: Fiscal 2011 Highlights
Recent Financial Performance 3 Fiscal 2011 Highlights Revenue grew 5.3 percent to $120.5 million. Gross profit grew 4.4 percent to $72.9 million on increased revenue and mix. Operating income increased $0.3 million, to $34.9 million Net income rose 3.6 percent to $24.5 million, or $2.58 per
Slide 4: Landauer Strategy Overview
Value Creation Deliver Upside Growth 1.Optimize Core 2.Competitive Growth 3. Strategic Expansion Strategic Priorities Landauer Strategy Overview Strategic ExpansionOptimize the Core Competitive Growth New Management in 2006 Restructure: Cost IT/ERP system upgrades OSL / InLight –new internat
Slide 5: Radiation Safety Continuum
Radiation Safety Continuum Existing Services with Penetration Opportunities* Complementary Adjacent Products / Services _____________________ (1) Average Revenue per Facility greater than $400K. Along the Radiation Safety Continuum 5 IZI Medical Physics Core Business Greater than $1.1 Billion US Mar
Slide 6: Competitive Growth: Penetration with US Military
6 Competitive Growth Penetration with US Military Expanding application of next generation technology to pursue global military and first responder radiation monitoring markets The U.S. military issued orders totaling $14.5 million to upgrade the Army’s tactical dosimetry capabilities, which wil
Slide 7: Emergency Response Mutual Aid / Synchronization
Emergency Response Mutual Aid / Synchronization 7
Slide 8: Strategic Expansion - Medical Physics
Strategic Expansion –Medical Physics Market Dynamics / OpportunityHighlights x $1.0 billion domestic market (largest player in market –by 3x) x Approximately 6,000 hospitals perform 37 million nuclear medicine procedures per year (10 million in U.S.) x Radiopharmaceutical utilization growing at over
Slide 9: Strategic Expansion - IZI Medical Products: Acquisition Overview
Strategic Expansion –IZI Medical Products Acquired 100% of the outstanding equity of IZI Medical Products for approximately $93 million cash, subject to certain customary purchase price adjustments The acquisition is expected to be $0.12 to $0.16 accretive to EPS (earnings per share) in fiscal 2
Slide 10: Strategic Expansion - IZI Medical Products: Transaction Rationale
10 Strategic Expansion –IZI Medical Products IZI represents a logical extension of Landauer’s radiation safety continuum ― Significant channel leverage for expanded product offering ― Enhances complementary product / service offerings ― Accretive both financially and operationally ― Broadens addre
Slide 11: Optimize the Core: Systems Initiative Update
11 Optimize the Core Systems Initiative Update We are on schedule to support “Go-Live”of the final phase of the project in fiscal 2012 Substantial expense will be incurred in fiscal 2012 to support the successful launch of the system – $4.4 million ($2.9 million net of tax) of non-recurring expe
Slide 12: LDR Dividend Policy
12 LDR Dividend Policy We are committed to maintaining a competitive dividend and will continue to return cash to shareholders in this manner going forward Board of Directors declared a regular quarterly cash dividend of$0.55 per share for the first quarter of fiscal 2012 – This represents an an
Slide 13: Guidance: Fiscal 2012 Outlook
Guidance 13 Fiscal 2012 Outlook Expected Revenue $150 to $157 million, which includes 10 months of contributions from the recent IZI Medical Products acquisition. Also reflects: – $4.4 million ($2.9 million net of tax) of non-recurring expense spending to support the successful completion of the C
Slide 14: Questions?
Questions? Fiscal 2011 Fourth Quarter and Year End Results December 6 th , 2011